amitriptyline has been researched along with Gout in 2 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
Gout: Metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of URIC ACID calculi.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using in silico docking analysis, RT-PCR, siRNA, elisa, proteomics and clinical data mining of drug consumption, we explored the clinical relevance of amitriptyline blockade of TLR4-mediated innate immune responses in human osteoarthritis chondrocytes." | 8.12 | Amitriptyline blocks innate immune responses mediated by toll-like receptor 4 and IL-1 receptor: Preclinical and clinical evidence in osteoarthritis and gout. ( Alonso-Pérez, A; Belén Bravo, S; Crespo-Golmar, A; Franco-Trepat, E; Gómez Bahamonde, R; Gualillo, O; Guillán-Fresco, M; Jorge-Mora, A; López-Fagúndez, M; Pazos-Pérez, A, 2022) |
| "Using in silico docking analysis, RT-PCR, siRNA, elisa, proteomics and clinical data mining of drug consumption, we explored the clinical relevance of amitriptyline blockade of TLR4-mediated innate immune responses in human osteoarthritis chondrocytes." | 4.12 | Amitriptyline blocks innate immune responses mediated by toll-like receptor 4 and IL-1 receptor: Preclinical and clinical evidence in osteoarthritis and gout. ( Alonso-Pérez, A; Belén Bravo, S; Crespo-Golmar, A; Franco-Trepat, E; Gómez Bahamonde, R; Gualillo, O; Guillán-Fresco, M; Jorge-Mora, A; López-Fagúndez, M; Pazos-Pérez, A, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Franco-Trepat, E | 1 |
| Alonso-Pérez, A | 1 |
| Guillán-Fresco, M | 1 |
| Jorge-Mora, A | 1 |
| Crespo-Golmar, A | 1 |
| López-Fagúndez, M | 1 |
| Pazos-Pérez, A | 1 |
| Gualillo, O | 1 |
| Belén Bravo, S | 1 |
| Gómez Bahamonde, R | 1 |
| Kilpatrick, R | 1 |
| Smith, AJ | 1 |
1 review available for amitriptyline and Gout
| Article | Year |
|---|---|
Advances in medicine.
Topics: Amitriptyline; Cholera; Coronary Disease; Crohn Disease; Diabetes Mellitus; Diet Therapy; Diverticul | 1971 |
1 other study available for amitriptyline and Gout
| Article | Year |
|---|---|
Amitriptyline blocks innate immune responses mediated by toll-like receptor 4 and IL-1 receptor: Preclinical and clinical evidence in osteoarthritis and gout.
Topics: Aged; Amitriptyline; Chondrocytes; Gout; Humans; Immunity, Innate; NLR Family, Pyrin Domain-Containi | 2022 |